Huberman LabDr. Pașca on Huberman Lab: How Assembloids Cure Autism
Assembloids are lab-grown brain circuits from stem cells in a dish; Pașca uses them to map what goes wrong in profound autism, epilepsy, and schizophrenia.
CHAPTERS
- 4:00 – 19:10
Defining Autism: Spectrum, Severity, and Genetics
Pașca explains that autism is a behaviorally defined spectrum condition with no biomarker, ranging from high‑functioning individuals to profoundly impaired children requiring lifelong care. He reviews the historical shift from psychoanalytic ‘refrigerator mother’ theories to twin studies demonstrating strong heritability, and he introduces the concept of “profound autism” linked to specific genetic mutations and associated comorbidities.
- •Autism prevalence is now close to 3% of the population and has risen significantly over recent decades.
- •Diagnosis is based solely on behavior (presence/absence of specific features), not lab tests or imaging.
- •Early psychoanalytic theories blaming cold parenting were overturned by twin and family studies showing strong genetic contribution.
- •Hundreds of genes are now associated with autism, particularly in severe, syndromic forms that include epilepsy and intellectual disability.
- •Autism should be thought of as many different biological disorders that share overlapping behavioral criteria, not a single disease entity.
- 19:10 – 42:00
Sex Differences, Diagnosis, and Questionable Environmental Links
The discussion turns to male–female differences in autism prevalence, potential underdiagnosis in girls, and biological resilience differences in premature infants. Pașca and Huberman then address popular but weakly supported hypotheses about fever, microbiome, vaccines, and environmental toxins, contrasting them with robust genetic evidence.
- •Autism is diagnosed 3–4 times more often in males; reasons include both biology and diagnostic biases.
- •Female brains may be more resilient around birth, and girls often reach developmental milestones earlier, possibly altering vulnerability windows.
- •Eye contact and joint attention deficits are common but not diagnostic or specific to autism.
- •Reports of symptom improvement during fevers are mostly anecdotal and could reflect generalized arousal or ion channel effects.
- •Microbiome and diet likely influence quality of life but currently lack strong evidence as primary causes of autism.
- •Large epidemiologic studies do not support a causal link between vaccination and autism; the strongest data point to genetics.
- 42:00 – 1:00:00
Why Autism Prevalence is Rising and the Limits of Correlation
Pașca parses the factors behind rising autism rates—broader criteria, diagnostic migration, and service incentives—while emphasizing that they cannot fully account for the increase. Huberman raises examples of contested environmental correlations (influenza in pregnancy, Amish populations, chemicals), and Pașca explains the pitfalls of correlational thinking and the importance of showing reversible causality, which is nearly impossible directly in humans.
- •Changes in diagnostic definitions and greater awareness have increased recorded autism prevalence but likely don’t explain it all.
- •Some children once labeled as intellectually disabled would now be classified as autistic; about one‑third of autistic individuals also have intellectual disability.
- •Environmental factors like thalidomide in pregnancy clearly increase risk, but such dramatic exposures are rare today.
- •Schizophrenia and other psychiatric illnesses appear at similar rates across cultures and isolated populations, underscoring strong genetic components.
- •You can’t ethically switch putative causes on and off in human brains, making causal inference far harder than in other fields.
- •The long, slow course of human brain development further complicates linking early exposures to adult psychiatric outcomes.
- 1:00:00 – 1:20:00
Gene Therapy, CRISPR, and Practical Constraints for Brain Disorders
The conversation shifts to gene therapy and CRISPR as conceptual tools for correcting disease‑causing mutations. Pașca outlines different strategies—adding a gene, supplying an enzyme, editing DNA versus targeting RNA—while emphasizing delivery, gene size, immune responses, and timing as major hurdles for treating brain diseases.
- •Gene therapy spans multiple approaches: viral gene addition, enzyme replacement, DNA editing, and RNA‑targeting therapies.
- •In blood diseases (e.g., sickle cell), CRISPR can be applied relatively directly; in the brain, access and cell‑type specificity are far more complex.
- •Large genes like calcium channels exceed the cargo capacity of many viral vectors, constraining classical gene‑addition strategies.
- •Immune responses to viral vectors often limit patients to a single systemic dose, which is risky for experimental CNS therapies.
- •Editing every affected neuron in a distributed brain circuit is currently infeasible; intervening at the RNA or signaling pathway level is often more realistic.
- •For neurodevelopmental disorders, the key translational question is “how early is too late?”—by adulthood, many developmental mis‑wiring events may be only partially reversible.
- 1:20:00 – 1:36:00
Stem Cell Hype vs Reality: Umbilical Banking and Offshore Clinics
Huberman raises common public questions about umbilical cord banking and commercial stem cell therapies offered abroad. Pașca clarifies that umbilical cells are lineage‑restricted and mostly useful for blood diseases, and he strongly criticizes poorly regulated stem cell injections for autism and CNS conditions as lacking biological rationale and proper clinical evidence.
- •Umbilical cord stem cells are hematopoietic/mesenchymal and mainly applicable to blood or immune disorders, not broad organ regeneration.
- •Many advertised “stem cell” interventions do not clearly disclose cell source, type, or differentiation state.
- •For autism, there is no evidence that intravenous stem cells can home to the brain and rewire complex circuits.
- •Parents’ reports of improvement after offshore treatments are susceptible to placebo effects, developmental changes, and transient inflammation/fever effects.
- •CNS injections carry real risks of infection, ectopic growth, and tumor formation; the FDA has shut down unsafe U.S. clinics, including eye injections that caused blindness.
- •Well‑designed, indication‑specific stem cell trials are needed, but indiscriminate use is more likely to harm than help.
- 1:36:00 – 1:52:00
From Yamanaka Factors to Patient‑Specific Neurons
Pașca walks through the revolution started by Shinya Yamanaka: reprogramming adult skin cells into induced pluripotent stem cells using a small set of factors. This bypasses the need for embryonic tissue, resolves major ethical debates, and provides virtually limitless patient‑specific cells to model disease and test interventions.
- •Stem cells are defined by two properties: self‑renewal and potency to differentiate into other cell types.
- •Embryonic pluripotent stem cells raised ethical concerns because they require destruction of early embryos.
- •Yamanaka’s discovery that four transcription factors can revert skin cells into pluripotent stem cells (iPSCs) was a paradigm shift.
- •iPSCs are functionally similar to embryonic stem cells but can be generated from any living person with a skin biopsy.
- •This enables disease modeling: derive iPSCs from patients, differentiate them into neurons or other cells, and observe disease‑specific alterations in vitro.
- •Early iPSC‑derived neurons from Timothy syndrome patients already showed prolonged calcium influx consistent with the known channel mutation.
- 1:52:00 – 2:10:00
Organoids: 3D Self‑Organizing Human Brain Tissue in a Dish
Moving beyond 2D neurons, Pașca describes the development of 3D brain organoids: floating spheroids of human neural tissue that self‑organize into layered cortical‑like structures and can be maintained for years. Remarkably, they follow human developmental timelines, including the prenatal–postnatal NMDA receptor subunit switch.
- •2D monolayer cultures are limited for modeling layered cortex and long‑term development; cells peel off and die over months.
- •By preventing cells from adhering to plastic and allowing them to aggregate, 3D organoids form that better mimic brain architecture.
- •Pașca’s lab has kept human cortical organoids alive for over 800 days, tracking maturation.
- •Molecular profiling shows that organoids recapitulate in vivo temporal programs, including the NR2B→NR2A NMDA receptor subunit switch around nine months.
- •This implies an intrinsic developmental “timer” in human neurons independent of birth, hormones, or environment.
- •Understanding this timer could eventually allow controlled acceleration or rejuvenation of specific neuronal ages in vitro.
- 2:10:00 – 2:41:00
Assembloids: Building Functional Human Brain Circuits
Pașca introduces assembloids—fused organoids that model interactions between brain regions. He recounts naming assembloids with Ben Barres and describes key examples: interneuron migration into cortex, cortico‑spinal‑muscle motor circuits that can drive contractions, and four‑node pain circuits that reveal subtle channelopathy phenotypes.
- •Many brain cell types originate in distinct regions and then migrate; assembloids model this by fusing region‑specific organoids.
- •First assembloids fused inhibitory neuron–producing organoids with cortical organoids; interneurons spontaneously migrated along correct trajectories.
- •A cortico‑spinal‑muscle assembloid models the simplest motor circuit: cortical neuron → spinal motor neuron → muscle; cortical stimulation triggers muscle contractions.
- •A four‑part somatosensory assembloid (sensory neurons, spinal cord, thalamus, cortex) self‑organizes into a functional pain pathway.
- •Inherited sodium channel mutations causing pain hypersensitivity or insensitivity selectively alter activity patterns at different nodes in this pathway.
- •Assembloids reveal emergent, distributed phenotypes—such as failures of synchronized propagation—that are invisible in single‑region or single‑cell models.
- 2:41:00 – 2:54:00
Transplanting Human Organoids into Rat Brains
To overcome limitations of in vitro environments, Pașca’s team transplants human cortical organoids into neonatal rat somatosensory cortex. The grafts vascularize, expand, and integrate functionally, acquiring more realistic size and morphology and allowing in vivo testing of candidate therapies on human neurons in a living brain context.
- •In vitro pyramidal neurons are ~10× smaller than those in human cortex, suggesting missing in vivo cues.
- •Transplanting human cortical organoids into the neonatal rat cortex yields large, vascularized grafts comprising a significant part of one hemisphere.
- •Timing is crucial: early postnatal rat brain is permissive; adult brain is much less so.
- •Human graft neurons respond to rat whisker stimulation, indicating functional sensory input into the human tissue.
- •Within the rat, human pyramidal neurons reach sizes and morphologies much closer to those in human brain tissue.
- •This chimera model allows testing of therapeutics (e.g., antisense oligos) on human cells in vivo before first‑in‑human trials.
- 2:54:00 – 3:17:00
Ethics, Language, and Misconceptions About “Mini Brains”
They tackle ethical questions around organoids and chimeras: consent for cell use, animal welfare in transplantation, and the possibility of emergent properties such as learning or sentience. Pașca stresses the importance of precise terminology and notes the community’s efforts to standardize nomenclature and best practices.
- •Ethical issues fall into three buckets: human tissue consent; animal welfare; and potential emergent properties from complex organoid or chimera systems.
- •There is currently no evidence that neural organoids are sentient or conscious; they lack whole‑brain architecture and key regions processing emotion and self‑awareness.
- •Terms like “mini brains” are scientifically misleading and unnecessarily alarming; the field now discourages them.
- •An international consortium developed consensus nomenclature and reporting standards for organoids and assembloids, published in Nature and Science.
- •Ethical reflection should happen at the design stage of experiments, not only after new capabilities appear.
- •Integration in chimeras depends on species distance and developmental stage, creating natural constraints and informing ethical boundaries.
- 3:17:00 – 3:35:00
Timothy Syndrome: A Prototype Stem‑Cell–Guided Cure
Pașca explains how methodical work on Timothy syndrome, a monogenic calcium channel disorder causing profound autism and epilepsy, led from basic iPSC modeling to an RNA‑based therapeutic candidate. Lubert Stryer’s reaction highlights how this demystifies psychiatric disease by linking behavior to a single nucleotide and a correctable molecular pathway.
- •Timothy syndrome arises from a single base substitution in a calcium channel gene, causing the channel to stay open longer and increasing calcium influx.
- •2D neurons revealed altered calcium dynamics; organoids and in vivo chimeras exposed additional phenotypes, such as reduced neuronal size.
- •Over ~15 years, the lab mapped the channel’s misprocessing and cell‑type–specific effects at multiple levels of organization.
- •They designed a short nucleic acid that modifies how the channel’s mRNA is processed, normalizing function.
- •This oligo rescues all measured cellular phenotypes in patient‑derived models; manufacturing and a first‑in‑human trial are underway.
- •It will be the first psychiatric‑related therapy developed entirely through human stem‑cell models, without a classical animal disease model.
- 3:35:00 – 3:52:00
Beyond Autism: Epilepsy, Schizophrenia, and Dystonia
Looking forward, Pașca outlines how similar workflows are being applied to genetic epilepsies, high‑risk schizophrenia syndromes like 22q11.2 deletion, and severe movement disorders such as dystonia. Loop assembloids modeling basal ganglia circuits are being built to pinpoint where in the loop mutations act and where therapies should be targeted.
- •Severe, genetic epilepsies with dozens of daily seizures are prime candidates for circuit‑level modeling and targeted therapies.
- •22q11.2 deletion syndrome, the most common human microdeletion, carries ~30% risk each for schizophrenia and autism, making it a powerful entry point into psychosis biology.
- •Penetrance varies widely; some carriers are mildly affected, highlighting the importance of genetic background and compensation.
- •Basal ganglia loop assembloids (cortex–striatum–midbrain–thalamus) are being developed to model dystonia and dyskinesias.
- •These models can show which node of the motor circuit is most perturbed by a given mutation, guiding where and how to intervene.
- •While high‑heritability, monogenic disorders are the near‑term focus, insights will likely generalize to more complex, polygenic conditions.
- 3:52:00
Personal Motivation, Work Ethic, and Closing Reflections
In closing, Pașca reflects on his motivations as a physician‑scientist, his near‑constant engagement with science, and the joy he finds in walking and art. Huberman underscores how Pașca’s work bridges basic biology and real therapies for devastating brain disorders, and they emphasize the need for careful communication as the field advances.
- •Pașca views his work as a source of fascination rather than “work,” and thinks about it nearly all waking hours.
- •His clinical experience with children with profound autism and severe psychiatric illness strongly motivates his research choices.
- •He maintains high energy and clarity through extensive daily walking (12–15k steps) and a long‑standing one‑meal‑per‑day routine.
- •Art and frequent museum visits provide a non‑scientific but intellectually nourishing counterbalance.
- •Huberman sees organoid/assembloid‑based neuroscience as the most promising route to curing many neurologic and psychiatric diseases.
- •Both stress that science is self‑correcting, dependent on new methods, and must be communicated to the public with precision and humility.
